Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Diabetes & Metabolic Disorders
Published in: Journal of Diabetes & Metabolic Disorders 1/2019

01-06-2019 | Insulins | Review Article

Prospective of managing impaired brain insulin signalling in late onset Alzheimers disease with excisting diabetic drugs

Authors: Gifty M. Jojo, Gowthamarajan Kuppusamy, Kousalya Selvaraj, Uday Krishna Baruah

Published in: Journal of Diabetes & Metabolic Disorders | Issue 1/2019

Login to get access

Abstract

Late onset Alzheimer’s disease (AD) is the most common cause of dementia among elderly. The exact cause of the disease is until now unknown and there is no complete cure for the disease. Growing evidence suggest that AD is a metabolic disorder associated with impairment in brain insulin signalling. These findings enriched the scope for the repurposing of diabetic drugs in AD management. Even though many of these drugs are moving in a positive direction in the ongoing clinical studies, the extent of the success has seen to influence by several properties of these drugs since they were originally designed to manage the peripheral insulin resistance. In depth understandings of these properties is hence highly significant to optimise the use of diabetic drugs in the clinical management of AD; which is the primary aim of the present review article.
Literature
1.
Pivi GAK, De Andrade NM, Da Ponte JB, De Moraes DS, Bertolucci PHF. Nutritional management for Alzheimer’s disease in all stages: mild, moderate, and severe. Nutrire. 2017;42:1.CrossRef
2.
Mufson EJ, Counts SE, Perez SE, Ginsberg SD, et al. Cholinergic system during the progression of Alzheimer's disease: Therapeutic implications. Expert Rev Neurother. 2008;8(11):1703–18.CrossRefPubMedPubMedCentral
3.
Wenk G L. Neuropathologic changes in Alzheimer's disease: potential targets for treatment. J Clin Psychiatry. 2006;67 Suppl 3:3–7; quiz 23.
4.
Wenk GL, Parsons CG, Danysz W. Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine. Behav Pharmacol. 2006;17:411–24.CrossRefPubMed
5.
Teipel SJ, Meindl T, Grinberg L, Grothe M, Cantero JL, Reiser MF, et al. The cholinergic system in mild cognitive impairment and Alzheimer's disease: an in vivo MRI and DTI study. Hum Brain Mapp. 2011;32:1349–62.CrossRefPubMed
6.
Dong S, Duan Y, Hu Y, Zhao Z. Advances in the pathogenesis of Alzheimer’s disease: a re-evaluation of amyloid cascade hypothesis. Transl Neurodegeneration. 2012;1(1):18.CrossRef
7.
8.
Herrmann N, Chau S, Kircanski I, Lanctôt KL. Current and emerging drug treatment options for Alzheimer’s disease: a systematic review. Drugs. 2011;71:2031–65.CrossRefPubMed
9.
10.
Anan R, Kiran DG, Abbas AM. Therapeutics of Alzheimer’s disease: past, present and future. Neuropharmacology. 2014;76:27–50.CrossRef
11.
Watson GS, Craft S. The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs. 2003;17(1):27–45.CrossRefPubMed
12.
Candeias E, Duarte AI, Carvalho C, Correia SC, Cardoso S, Santos RX, et al. The impairment of insulin signaling in Alzheimer's disease. IUBMB Life. 2012;64(12):951–7.CrossRefPubMed
13.
Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. Deficient brain insulin signalling pathway in Alzheimer’s disease and diabetes. J Pathol. 2011;225(1):54–62.CrossRefPubMedPubMedCentral
14.
15.
Kalaria RN. Neurodegenerative disease: diabetes, microvascular pathology and Alzheimer disease. Nat Rev Neurol. 2009;5:305–6.CrossRefPubMed
16.
17.
Mullin, Rick. (2014) "Cost to develop new pharmaceutical drug now exceeds $2.5B". Scientific American.
18.
19.
Talbot K. Brain insulin resistance in Alzheimer's disease and its potential treatment with GLP-1 analogs. Neurodegenerative Dis Manag. 2014;4(1):31–40.CrossRef
20.
21.
Jolivalt CG, Lee CA, Beiswenger KK, Smith JL, Orlov M, Torrance MA, et al. Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice:parallels with alzheimer’s disease and correction by insulin. J Neurosci Res. 2008;86:3265–74.CrossRefPubMedPubMedCentral
22.
Ryu BR, Ko HW, Jou I, Gwag BJ. Phosphatidylinositol 3-kinase-mediated regulation of neuronal apoptosis and necrosis by insulin and IGF-I. J Neurobiol. 1999;39(4):536–46.CrossRefPubMed
23.
Min Son S, Song H, Byun J, Park KS, Jang HC, Park YJ, et al. Altered APP processing in insulin-resistant conditions is mediated by autophagosome accumulation via the inhibition of mammalian target of rapamycin pathway. Diabetes. 2012;61(12):3126–38.CrossRef
24.
Pandini G, Pace V, Copani A, Squatrito S, Milardi D, Vigneri R. Insulin has multiple antiamyloidogenic effects on human neuronal cells. Endocrinology. 2013;154:375–87.CrossRefPubMed
25.
Messier C, Teutenberg K. The role of insulin, insulin growth factor, and insulin-degrading enzyme in brain aging and Alzheimer's disease. Neural Plasticity. 2005;12(4):311–28.CrossRefPubMedPubMedCentral
26.
Pivovarova O, Hohn A, Grune T, Pfeiffer AF, Rudovich N. Insulin-degrading enzyme: new therapeutic target for diabetes and Alzheimer's disease? Ann Med. 2016;48(8):614–24.CrossRefPubMed
27.
Qiu WQ, Folstein MF. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer’s disease: review and hypothesis. Neurobiol Aging. 2006;27(2):190–8.CrossRefPubMed
28.
Xie L, Helmerhorst E, Taddei K, Plewright B, Van Bronswijk W, Martins R. Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor. J Neurosci. 2002;22(10):RC221.CrossRefPubMed
29.
Havrankova J, Roth J, Brownstein M. Insulin receptors are widely distributed in the central nervous system of the rat. Nature. 1978;272:827–9.CrossRefPubMed
30.
Bingham EM, Hopkins D, Smith D, Pernet A, Hallett W, Reed L, et al. The role of insulin in human brain glucose metabolism: an 18fluoro-deoxyglucose positron emission tomography study. Diabetes. 2002;51:3384–90.CrossRefPubMed
31.
Figlewicz DP, Szot P, Israel PA, Payne C, Dorsa DM. Insulin reduces norepinephrine transporter mRNA in vivo in rat locus coeruleus. Brain Res. 1993;602:161–4.CrossRefPubMed
32.
Kopf SR, Baratti CM. Effects of post training administration of insulin on retention of a habituation response in mice:participation of a central cholinergic mechanism. Neurobiol Learn Mem. 1999;71:50–61.CrossRefPubMed
33.
Kaiyala KJ, Prigeon RL, Kahn SE, Woods SC, Schwartz MW. Obesity induced by a high-fat diet is associated with reduced brain insulin transport in dogs. Diabetes. 2000;49:1525–33.CrossRefPubMed
34.
Park K, Gross M, Lee DH, Holvoet P, Himes JH, Shikany JM, et al. Oxidative stress and insulin resistance: the coronary artery risk development in young adults study. Diabetes Care. 2009;32(7):1302–7.CrossRefPubMedPubMedCentral
35.
Henriksen EJ, Diamond-Stanic MK, Marchionne EM. Oxidative stress and the etiology of insulin resistance and type 2 diabetes. Free Radic Biol Med. 2011;51(5):993–9.CrossRefPubMed
36.
37.
MacKnight C, Rockwood K, Awalt E, McDowell I. Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian study of health and aging. Dement Geriatr Cogn Disord. 2002;14:77–83.CrossRefPubMed
38.
Frolich L, Blum-Degen D, Bernstein HG, et al. Brain insulin and insulin receptors in aging and sporadic Alzheimer’s disease. J Neural Transm (Vienna). 1998;105:423–38.CrossRef
39.
Chakrabarti S, Munshi S, Banerjee K, ThakurtaI G, et al. Mitochondrial dysfunction during brain aging: role of oxidative stress and modulation by antioxidant supplementation. Aging Dis. 2011;2(3):242–56.PubMedPubMedCentral
40.
Liu R, Liu IY, Bi X, Thompson RF, Doctrow SR, Malfroy B, et al. Reversal of age-related learning deficits and brain oxidative stress in mice with superoxide dismutase/catalase mimetics. Proc Natl Acad Sci U S A. 2003;100(14):8526–31.CrossRefPubMedPubMedCentral
41.
Floyd RA, Hensley K. Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases. Neurobiol Aging. 2002;23(5):795–807.CrossRefPubMed
42.
Mariani E, Polidori MC, Cherubini A, Mecocci P. Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J Chromatogr B Anal Technol Biomed Life Sci. 2005;827(1):65–75.CrossRef
43.
Muller DC, Elahi D, Tobin JD, Andres R. The effect of age on insulin resistance and secretion: a review. Semin Nephrol. 1996;16(4):289–98.PubMed
44.
Sartorius T, Peter A, Heni M, Maetzler W, Fritsche A, Häring HU, et al. The brain response to peripheral insulin declines with age: a contribution of the blood-brain barrier? PLoS One. 2015;10(5):e0126804.CrossRefPubMedPubMedCentral
45.
Kullmann S, Heni M, Hallschmid M, Fritsche A, Preissl H, Häring HU. Brain insulin resistance at the crossroads of metabolic and cognitive disorders in humans. Physiol Rev. 2016;96:1169–209.CrossRefPubMed
46.
Simpson IA, Chundu KR, Davies-Hill T, Honer WG, Davies P. Decreased concentrations of glut1 and glut3 glucose transporters in the brain of patients with Alzheimer’s disease. Ann Neurol. 1994;35:546–51.CrossRefPubMed
47.
Simpson IA, Davies P. Reduced glucose transporter concentrations in brains of patients with Alzheimer’s disease. Ann Neurol. 1994;36:800–1.CrossRefPubMed
48.
Harik SI. Changes in the glucose transporter of brain capillaries. Can J Physiol Pharmacol. 1992;70:S113–7.CrossRefPubMed
49.
Kalaria RN, Harik SI. Reduced glucose transporter at the blood-brain barrier and in cerebral cortex in Alzheimer’s disease. J Neurochem. 1989;53:1083–8.CrossRefPubMed
50.
Liu Y, Liu F, Iqbal K, Grundke-Iqbal I, Gong CX. Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease. FEBS Lett. 2008;582:359–64.CrossRefPubMedPubMedCentral
51.
Uemura E, Greenlee HW. Insulin regulates neuronal glucose uptake by promoting translocation of glucose transporter GLUT3. Exp Neurol. 2006;198(1):48–53.CrossRefPubMed
52.
McEwen BS, Reagan LP. Glucose transporter expression in the central nervous system: relationship to synaptic function. Eur J Pharmacol. 2004;490:13–24.CrossRefPubMed
53.
Liu F, Iqbal K, Grundke-Iqbal I, Hart GW, Gong CX. O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc Natl Acad Sci U S A. 2004;101(29):10804–9.CrossRefPubMedPubMedCentral
54.
Li X, Lu F, Wang JZ, Gong CX. Concurrent alterations of O-GlcNAcylation and phosphorylation of tau in mouse brains during fasting. Eur J Neurosci. 2006;23(8):2078–86.CrossRefPubMed
55.
Winkler EA, Nishida Y, Sagare AP, Rege SV, Bell RD, Perlmutter D, et al. GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration. Nat Neurosci. 2015;18(4):521–30.CrossRefPubMedPubMedCentral
56.
Arluison M, Quinon M, Thorens B, Leloup C, et al. Immunohistochemical localization of the glucose transporter 2 (GLUT2) in the adult rat brain. II Electron microscopic study. J Chem Neuroanat. 2004;28:137–46.CrossRefPubMed
57.
Arluison M, Quinon M, Nguyen P, Thorens B, et al. Distribution and anatomical localization of the glucose transporter 2 (GLUT2) in the adult rat brain-an-immunohistochemical study. J Chem Neuroanat. 2004;28:117–36.CrossRefPubMed
58.
Vannucci SJ, Koehler-Stec EM, Li K, Reynolds TH, Clark R, Simpson IA. GLUT4 glucose transporter expression in rodent brain: effect of diabetes. Brain Res. 1998;797:1–11.CrossRefPubMed
59.
Winocur G, Greenwood CE, Piroli GG, Grillo CA, Reznikov LR, Reagan LP, et al. Memory impairment in obese Zucker rats: an investigation of cognitive function in an animal model of insulin resistance and obesity. Behav Neurosci. 2005;119(5):1389–95.CrossRefPubMed
60.
Piroli GG, Grillo CA, Reznikov LR, Adams S, McEwen BS, Charron MJ, et al. Corticosterone impairs insulin-stimulated translocation of GLUT4 in the rat hippocampus. Neuroendocrinology. 2007;85(2):71–80.CrossRefPubMed
61.
Lebovitz HE. Insulin resistance: definition and consequences. Exp Clin Endocrinol Diabetes. 2001;109(Suppl 2):S135–48.CrossRefPubMed
62.
Kulstad JJ, Green PS, Cook DG, Watson GS, Reger MA, Baker LD, et al. Differential modulation of plasma beta-amyloid by insulin in patients with Alzheimer disease. Neurology. 2006;66(10):1506–10.CrossRefPubMed
63.
Craft S, Asthana S, Newcomer JW, Wilkinson CW, Matos IT, Baker LD, et al. Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch Gen Psychiatry. 1999;56(12):1135–40.CrossRefPubMed
64.
65.
Ferrannini E, Galvan AQ, Santoro D, Donatella S, Andrea N. Potassium as a link between insulin and the renin-angiotensin-aldosterone system. J Hypertens. 1992;10(1):S5–10.CrossRef
66.
Barbagallo M, Dominguez LJ, Galioto A, Ferlisi A, Cani C, Malfa L, et al. Role of magnesium in insulin action, diabetes and cardio-metabolic syndrome X. Mol Asp Med. 2003;24:39–52.CrossRef
67.
68.
Hanson LR, Frey WH II. Intranasal delivery bypasses the blood brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci. 2008;9:S5.CrossRefPubMedPubMedCentral
69.
70.
Schiöth HB, Craft S, Brooks SJ, Frey WH 2nd, Benedict C. Brain insulin signaling and Alzheimer's disease: current evidence and future directions. Mol Neurobiol. 2012;46(1):4–10.CrossRefPubMed
71.
Hu SH, Jiang T, Yang SS, Yang Y. Pioglitazone ameliorates intracerebral insulin resistance and tau-protein hyperphosphorylation in rats with Type 2 Diabetes. Exp Clin Endocrinol Diabetes. 2013;121(4):220–4.CrossRefPubMed
72.
Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E, Borghgraef P, et al. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci U S A. 2006;103:443–8.CrossRefPubMedPubMedCentral
73.
d'Abramo C, Massone S, Zingg JM, Pizzuti A, Marambaud P, Dalla Piccola B, et al. Role of peroxisome proliferator-activated receptor gamma in amyloid precursor protein processing and amyloid beta-mediated cell death. Biochem J. 2005;391:693–8.CrossRefPubMedPubMedCentral
74.
Camacho IE, Serneels L, Spittaels K, Merchiers P, Dominguez D, de Strooper B. Peroxisome proliferator-activated receptor gamma induces a clearance mechanism forthe amyloid-beta peptide. J Neurosci. 2004;24:10908–17.CrossRefPubMed
75.
Bogacka I, Xie H, Bray GA, Smith SR. Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. Diabetes. 2005;54:1392–9.CrossRefPubMed
76.
Handschin C, Spiegelman BM. Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev. 2006;27:728–35.CrossRefPubMed
77.
Pathan AR, Viswanad B, Sonkusare SK, Ramarao P. Chronic administration of pioglitazone attenuates intracerebroventricular streptozotocin induced-memory impairment in rats. Life Sci. 2006;79:2209–16.CrossRefPubMed
78.
Qing-Qing Y, Jin-Jing P, Xu S, Ding-Zhen L, et al. Pioglitazone improves cognitive function via increasing insulin sensitivity and strengthening antioxidantdefense system in fructose-drinking insulin resistance rats. PLoS One. 2013;8(3):e59313.CrossRef
79.
Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol. 2002;2:748–59.CrossRefPubMed
80.
81.
Cho DH, Lee EJ, Kwon KJ, Shin CY, Song KH, Park JH, et al. Troglitazone, a thiazolidinedione, decreases tau phosphorylation through the inhibition of cyclin-dependent kinase 5 activity in SH-SY5Y neuroblastoma cells and primary neurons. J Neurochem. 126:685–95.
82.
Qu J, Nakamura T, Cao G, Holland EA, McKercher SR, Lipton SA. (2011) S-Nitrosylation activates Cdk5 and contributes to synaptic spine loss induced by beta-amyloid peptide. Proc Natl Acad Sci U S A. 2011;108(34):14330–5.CrossRefPubMedPubMedCentral
83.
84.
Jiang LY, Su-Su T, Wang XY, Liu LP, et al. PPARγ agonist pioglitazone reverses memory impairment and biochemical changes in a mouse model of type 2 diabetes mellitus. CNS Neurosci Ther. 2012;18:659–66.CrossRefPubMedPubMedCentral
85.
Li-ping L, Tian-hua Y, Li-ying J, Hu W, et al. Pioglitazone ameliorates memory deficits in streptozotocin-induced diabetic mice by reducing brain β-amyloid through PPARγ activation. Acta Pharmacol Sin. 2013;34:455–63.CrossRef
86.
Yin QQ, Pei JJ, Xu S, Luo DZ. Pioglitazone improves cognitive function via increasing insulin sensitivity and strengthening antioxidant defense system in fructose-drinking insulin resistance rats. PLoS One. 2013;8(3):e59313.CrossRefPubMedPubMedCentral
87.
Yang S, Chen Z, Cao M, Li R, et al. Pioglitazone ameliorates Aβ42 deposition in rats with diet-induced insulin resistance associated with AKT/GSK3β activation. Mol Med Rep. 2017;15(5):2588–94.CrossRefPubMedPubMedCentral
88.
Fernandez-Martos CM, Atkinson RAK, Chuah MI, King AE, Vickers JC. Combination treatment with leptin and pioglitazone in a mouse model of Alzheimer's disease. Alzheimers Dement. 2017;3:92–106.
89.
Maeshiba Y, Kiyota Y, Yamashita K, Yoshimura Y, Motohashi M, Tanayama S. Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. Arzneimittelforschung. 1997;47:29–35.PubMed
90.
Landreth G, Jiang Q, Mandrekar S, Heneka M. PPAR agonists as therapeutics for the treatment of Alzheimer’s disease. Am Soc Exp NeuroTher Inc. 2008;5:481–9.
91.
92.
Morgenweck J, Abdel-Aleem OS, McNamara KC, Donahue RR, et al. Activation of peroxisome proliferator activated receptor γ in brain inhibits inflammatory pain, dorsal horn expression of Fos, and local edema. Neuropharmacology. 2010;58(2):337.CrossRefPubMed
93.
Matias JA, Gilbert ER, Denbow DM, Cline MA. Effects of intracerebroventricular injection of rosiglitazone on appetite-associated parameters in chicks. Gen Comp Endocrinol. 2017;246:99–104.CrossRefPubMed
94.
Ou Z, Zhao X, Labiche LA, Strong R, Grotta JC, Herrmann O, et al. Neuronal expression of peroxisome proliferator-activated receptor-gamma (PPARgamma) and 15d-prostaglandin J2--mediated protection of brain after experimental cerebral ischemia in rat. Brain Res. 2006;1096(1):196–203.CrossRefPubMed
95.
Pedersen WA, McMillan PJ, Kulstad JJ, Leverenz JB, Craft S, Haynatzki GR. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol. 2006;199(2):265–73.CrossRefPubMed
96.
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–71.CrossRefPubMed
97.
Tuccori M, Filion KB, Yin H, Oriana HY, Platt RW, Azoulay L. Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ. 2016;352:i1541.CrossRefPubMedPubMedCentral
98.
99.
Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet. 2003;42(1):59–98.CrossRefPubMed
100.
101.
Geldmacher DS, Fritsch T, McClendon MJ, Landreth G. A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Arch Neurol. 2011;68(1):45–50.CrossRefPubMed
102.
Labuzek K, Suchy D, Gabryel B, Bielecka A, Liber S, Okopień B. Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide. Pharmacol Rep. 2010;62:956–65.CrossRefPubMed
103.
Chopra I, Li HF, Wang H, Webster KA. Phosphorylation of the insulin receptor by AMP-activated protein kinase (AMPK) promotes ligand-independent activation of the insulin signalling pathway in rodent muscle. Diabetologia. 2012;55(3):783–94.CrossRefPubMed
104.
Kitabchi AE, Temprosa M, Knowler WC, Kahn SE, Fowler SE, Haffner SM, et al. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes. 2005;54:2404–14.CrossRefPubMed
105.
Salminen A, Kaarniranta K, Haapasalo A, Soininen H, Hiltunen M. AMP-activated protein kinase: a potential player in Alzheimer's disease. J Neurochem. 2011;118(4):460–74.CrossRefPubMed
106.
Du LL, Chai DM, Zhao LN, Li XH, et al. AMPK activation ameliorates Alzheimer's disease-like pathology and spatial memory impairment in a streptozotocin-induced Alzheimer's disease model in rats. J Alzheimers Dis. 2015;43(3):775–84.CrossRefPubMed
107.
Cai Z, Yan LJ, Li K, Quazi SH, Zhao B. Roles of AMP-activated protein kinase in Alzheimer's disease. NeuroMol Med. 2012;14(1):1–14.CrossRef
108.
Price NL, Gomes AP, Ling AJ, Duarte FV, et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 2012;15(5):675–90.CrossRefPubMedPubMedCentral
109.
Gupta A, Bisht B, Dey CS. Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer’s like changes. Neuropharmacology. 2011;60:910–20.CrossRefPubMed
110.
Li J, Deng W, Sheng ZZ. Metformin attenuates Alzheimer’s disease-like neuropathology in obese, leptin-resistant mice. Pharmacol Biochem Behav. 2012;101(4):564–74.CrossRefPubMedPubMedCentral
111.
Hsu CC, Wahlqvist ML, Lee MS, Tsai HN. Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. J Alzheimers Dis. 2011;24(3):485–93.CrossRefPubMed
112.
Imfeld P, Bodmer M, Jick SS, Meier CR. Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case-control study. J Am Geriatr Soc. 2012;60(5):916–21.CrossRefPubMed
113.
Ng TP, Feng L, Yap KB, Lee TS. Long-term metformin usage and cognitive function among older adults with diabetes. J Alzheimers Dis. 2014;41(1):61–8.CrossRefPubMed
114.
Cheng C, Lin CH, Tsai YW, Tsai CJ, et al. Type 2 diabetes and antidiabetic medications in relation to dementia diagnosis. J Gerontol A Biol Sci Med Sci. 2014;69(10):1299–305.CrossRefPubMed
115.
Koenig AM, Mechanic-Hamilton D, Xie SX, Combs MF, Cappola AR, Xie L, et al. Effects of the insulin sensitizer metformin in Alzheimer disease: pilot data from a randomized placebo-controlled crossover study. Alzheimer Dis Assoc Disord. 2017;31(2):107–13.CrossRefPubMedPubMedCentral
116.
Andres E, Noel E, Goichot B. Metformin-associated vitamin B12 deficiency. Arch Intern Med. 2002;162(19):2251–2.CrossRefPubMed
117.
Kibirige D, Mwebaze R. Vitamin B12 deficiency among patients with diabetes mellitus: is routine screening and supplementation justified? J Diabetes Metab Disord. 2013;12(1):17.CrossRefPubMedPubMedCentral
118.
Ting RZ, Szeto CC, Chan MH, Ma KK, Chow KM. Risk factors of vitamin B(12) deficiency in patients receiving metformin. Arch Intern Med. 2006;166(18):1975–9.CrossRefPubMed
119.
Osimani A, Berger A, Friedman J, Porat-Katz BS, Abarbanel JM. Neuropsychology of vitamin B12 deficiency in elderly dementia patients and control subjects. J Geriatr Psychiatry Neurol. 2005;18(1):33–8.CrossRefPubMed
120.
Du LL, Chai DM, Zhao LN, Li XH, et al. AMPK activation ameliorates Alzheimer's disease-like pathology and spatial memory impairment in a streptozotocin-induced Alzheimer's disease model in rats. J Alzheimers Dis. 2015;43(3):775–84.CrossRefPubMed
121.
Domise M, Didier S, Marinangeli C, Zhao H, et al. AMP-activated protein kinase modulates tau phosphorylation and tau pathology in vivo. Sci Rep. 2016;6:26758.CrossRefPubMedPubMedCentral
122.
Vingtdeux V, Davies P, Dickson DW, Marambaud P. AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies. Acta Neuropathol. 2011;121(3):337–49.CrossRefPubMed
123.
Ma T, Chen Y, Vingtdeux V, Zhao H, Viollet B, Marambaud P, et al. Inhibition of AMP-activated protein kinase signaling alleviates impairments in hippocampal synaptic plasticity induced by amyloid β. J Neurosci. 2014;34(36):12230–8.CrossRefPubMedPubMedCentral
124.
Chen Y, Zhou K, Wang R, Liu Y, Kwak YD, Ma T, et al. Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc Natl Acad Sci U S A. 2009;106(10):3907–12.CrossRefPubMedPubMedCentral
125.
Picone P, Nuzzo D, Caruana L, Messina E, Barera A, Vasto S, et al. Metformin increases APP expression and processing via oxidative stress, mitochondrial dysfunction and NF-κB activation: use of insulin to attenuate metformin's effect. Biochim Biophys Acta. 2015;1853(5):1046–59.CrossRefPubMed
126.
Son SM, Shin HJ, Byun J, Kook SY, Moon M, Chang YJ, et al. Metformin facilitates amyloid-β generation by β- and γ-secretases via autophagy activation. J Alzheimers Dis. 2016;51(4):1197–208.CrossRefPubMed
127.
de Wet H, Proks P. Molecular action of sulphonylureas on KATP channels: a real partnership between drugs and nucleotides. Biochem Soc Trans. 2015;43(5):901–7.CrossRefPubMedPubMedCentral
128.
Betourne A, Bertholet AM, Labroue E, Halley H, Sun HS, Lorsignol A, et al. Involvement of hippocampal CA3 K (ATP) channels in contextual memory. Neuropharmacology. 2009;56(3):615–25.CrossRefPubMed
129.
Ghelardini C, Galeotti N, Bartolini A. Influence of potassium channel modulators on cognitive processes in mice. Br J Pharmacol. 1998;123(6):1079–84.CrossRefPubMedPubMedCentral
130.
Stefani MR, Nicholson GM, Gold PE. ATP-sensitive potassium channel blockade enhances spontaneous alternation performance in the rat: a potential mechanism for glucose-mediated memory enhancement. Neuroscience. 1999;93(2):557–63.CrossRefPubMed
131.
Salgado-Puga K, Rodríguez-Colorado J, Prado-Alcalá RA, Peña-Ortega F. Subclinical doses of ATP-sensitive Potassium Channel modulators prevent alterations in memory and synaptic plasticity induced by amyloid-β. J Alzheimers Dis. 2017;57(1):205–26.CrossRefPubMed
132.
Liu D, Pitta M, Lee JH, Ray B, Lahiri DK, Furukawa K, et al. The KATP channel activator diazoxide ameliorates amyloid-β and tau pathologies and improves memory in the 3xTgAD mouse model of Alzheimer's disease. J Alzheimers Dis. 2010;22(2):443–57.CrossRefPubMedPubMedCentral
133.
Awad N, Gagnon M, Messier C. The relationship between impaired glucose tolerance, type 2 diabetes, and cognitive function. J Clin Exp Neuropsychol. 2004;26(8):1044–80.CrossRefPubMed
134.
135.
Dorn A, Bernstein HG, Rinne A, Ziegler M, Hahn HJ, Ansorge S. Insulin- and glucagonlike peptides in the brain. Anat Rec. 1983;207:69–77.CrossRefPubMed
136.
Dorn A, Bernstein HG, Rinne A, Hahn HJ, Ziegler M. Insulin-like immunoreactivity in the human brain- a preliminary report. Histochemistry. 1982;74:293–300.CrossRefPubMed
137.
Ghasemi R, Haeri A, Dargahi L, Mohamed Z, Ahmadiani A. Insulin in the brain: sources, localization and functions. Mol Neurobiol. 2013;47:145–71.CrossRefPubMed
138.
Birch NP, Christie DL, Renwick AG. Proinsulin-like material in mouse foetal brain cell cultures. FEBS Lett. 1984;168:299–302.CrossRefPubMed
139.
Gerozissis K. Brain insulin: Regulation, mechanisms of action and functions. Cell Mol Neurobiol. 2003;23(1):1–25.CrossRefPubMed
140.
Ikeda M, Dewar D, McCulloch J. High affinity hippocampal [3H]-glibenclamide binding sites are preserved in Alzheimer's disease. J Neural Transm Park Dis Dement. 1993;5(3):177–84.CrossRef
141.
Griffith CM, Xie MX, Qiu WY, Sharp AA, Ma C, Pan A, et al. Aberrant expression of the pore-forming KATP channel subunit Kir6.2 in hippocampal reactive astrocytes in the 3xTg-AD mouse model and human Alzheimer's disease. Neuroscience. 2016;336:81–101.CrossRefPubMed
142.
143.
Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359(9309):824–30.CrossRefPubMed
144.
Yildirim Simsir I, Soyaltin UE, Cetinkalp S. Glucagon like peptide-1 (GLP-1) likes Alzheimer's disease. Diabetes Metab Syndr. 2018;12(3):469–75.CrossRefPubMed
145.
Calsolaro V, Edison P. Novel GLP-1 (glucagon-like peptide-1) analogues and insulin in the treatment for alzheimer’s disease and other neurodegenerative diseases. CNS Drugs. 2015;29(12):1023–39.CrossRefPubMed
146.
Campbell JE, Drucker DJ. Pharmacology: physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17(6):819–37.CrossRefPubMed
147.
Perfetti R, Zhou J, Doyle ME, Egan JM. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old: glucose-intolerant rats. Endocrinology. 2000;141(12):4600–5.CrossRefPubMed
148.
McClean PL, Parthsarathy V, Faivre E, Holscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer’s disease. J Neurosci. 2011;31(17):6587–94.CrossRefPubMedPubMedCentral
149.
McClean PL, Holscher C. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer’s disease. Neuropharmacology. 2014;76(Pt A):57–67.CrossRefPubMed
150.
McClean PL, Holscher C. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer’s disease. Neuropharmacology. 2014;86:241–58.CrossRefPubMed
151.
Li L, Zhang ZF, Holscher C, Gao C, Jiang YH, Liu YZ. (Val(8)) glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains. Eur J Pharmacol. 2012;674(2–3):280–6.CrossRefPubMed
152.
Hansen HH, Fabricius K, Barkholt P, Niehoff ML, Morley JE, Jelsing J, et al. The GLP-1 receptor agonist liraglutide improves memory function and increases hippocampal CA1 neuronal numbers in a senescence-accelerated mouse model of Alzheimer’s disease. J Alzheimers Dis. 2015;46(4):877–88.CrossRefPubMedPubMedCentral
153.
Gejl M, Gjedde A, Egefjord L, Moller A, Hansen SB, Vang K, et al. In alzheimer’s disease, 6-months treatment with glp-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial. Front Aging Neurosci. 2016;8:108.CrossRefPubMedPubMedCentral
154.
Gradman TJ, Laws A, Thompson LW, Reaven GM. Verbal learning and/or memory improves with glycemic control in older subjects with non-insulin-dependent diabetes mellitus. J Am Geriatr Soc. 1993;41(12):1305–12.CrossRefPubMed
155.
156.
Fewlass DC, Noboa K, Pi-Sunyer FX, Johnston JM, Yan SD, Tezapsidis N. Obesity-related leptin regulates Alzheimer's Abeta. FASEB J. 2004;18:1870–8.CrossRefPubMed
157.
Greco SJ, Sarkar S, Johnston JM, Zhu X, Su B, Casadesus G, et al. Leptin reduces Alzheimer's disease-related tau phosphorylation in neuronal cells. Biochem Biophys Res Commun. 2008;376:536–41.CrossRefPubMedPubMedCentral
158.
Letra L, Santana I, Seiça R. Obesity as a risk factor for Alzheimer's disease: the role of adipocytokines. Metab Brain Dis. 2014;29(3):563–8.CrossRefPubMed
159.
Myers MG Jr, Leibel RL, Seeley RJ, Schwartz MW. Obesity and leptin resistance: distinguishing cause from effect. Trends Endocrinol Metab. 2010;21(11):643–51.CrossRefPubMedPubMedCentral
160.
161.
Lieb W, Beiser AS, Vasan RS, Tan ZS, Au R, Harris TB, et al. Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. JAMA. 2009;302:2565–72.CrossRefPubMedPubMedCentral
162.
McGuire MJ, Ishii M. Leptin dysfunction and Alzheimer's disease: evidence from cellular, animal, and human studies. Cell Mol Neurobiol. 2016;36(2):203–17.CrossRefPubMedPubMedCentral
163.
164.
165.
166.
Berhanu P, Perez A, Yu S. Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy. Diabetes Obes Metab. 2007;9(4):512–20.CrossRefPubMed
167.
Reger MA, Watson GS, Frey WH 2nd, Baker LD, et al. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging. 2006;27(3):451–8 Epub 2005 Jun 16.CrossRefPubMed
168.
Reger MA, Watson GS, Green PS. Intranasal insulin improves cognition and modulates -amyloid in early AD. Neurology. 2008;70:440–8.CrossRefPubMed
169.
Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma β-amyloid in memory-impaired older adults. J Alzheimers Dis. 2008;13(3):323–31.CrossRefPubMedPubMedCentral
170.
Craft S, Baker LD, Montine TJ, Minoshima S, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol. 2012;69(1):29–38.CrossRefPubMed
171.
Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry. 2005;13(11):950–8.PubMed
172.
Tzimopoulou S, Cunningham VJ, Nichols TE, Searle G, Bird NP, Mistry P, et al. A multi-center randomized proof-of-concept clinical trial applying [18F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease. J Alzheimers Dis. 2010;22(4):1241–56.CrossRefPubMed
173.
Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease. Pharmacogenomics J. 2006;6(4):246–54.CrossRefPubMed
174.
Harrington C, Sawchak S, Chiang C, Davies J, Donovan C, Saunders AM, et al. Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies. Curr Alzheimer Res. 2011;8(5):592–606.CrossRefPubMed
175.
Hanyu H, Sato T, Kiuchi A, Sakurai H, Iwamoto T, et al. Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus. J Am Geriatr Soc. 2009;57(1):177–9.CrossRefPubMed
176.
177.
Li XL, Aou S, Oomura Y, Hori N, Fukunaga K, Hori T. Impairment of long-term potentiation and spatial memory in leptin receptor-deficient rodents. Neuroscience. 2002;113:607–15.CrossRefPubMed
Metadata
Title
Prospective of managing impaired brain insulin signalling in late onset Alzheimers disease with excisting diabetic drugs
Authors
Gifty M. Jojo
Gowthamarajan Kuppusamy
Kousalya Selvaraj
Uday Krishna Baruah
Publication date
01-06-2019
Publisher
Springer International Publishing
Published in
Journal of Diabetes & Metabolic Disorders / Issue 1/2019
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1007/s40200-019-00405-2

Other articles of this Issue 1/2019

Journal of Diabetes & Metabolic Disorders 1/2019 Go to the issue

Research article

Impact of alexithymia on glycemic control among Lebanese adults with type 2 diabetes

Research Article

In vivo studies demonstrate that endothelin-1 traps are a potential therapy for type I diabetes

Review Article

Ottawa charter framework as a guide for type 2 diabetes prevention and control in Iran

Review Article

A therapeutic approach towards microRNA29 family in vascular diabetic complications: A boon or curse?

Research Article

Insulin pump initiation and education for children and adolescents – a qualitative study of current practice in New Zealand

Research Article

Rationale of family medicine physicians in effectively identifying patients with chronic hyperglycemia through point-of-care hemoglobin A1C screenings
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits